Compugen presented a batch of data from early-stage trials of its anti-PVRIG candidate in dual and triple combination studies, including one with an anti-TIGIT therapy, but the pairings are no longer part of the biotech’s strategy after it recently axed a yearslong Bristol Myers Squibb collaboration.
And, for a brief...
